Exploration of Neuroscience

From: First outcomes of a therapeutic platform for drug resistant epilepsy based on transcutaneous electrical vagus nerve stimulation

Table 2

Seizure monthly rate evolution

ID	SMSR	M1	M2	M3	TAR1	M4	M5	M6	TAR2	M7	M8	M9	TAR3	SR (%)
P-01	13	21	13	27	20.33	9	23	9	13.67	9	6	23	12.67	2.56
P-02	4	0	0	0	0	0	0	0	0	1	0	0	0.33	91.67
P-03	7	4	7	4	5	6	5	10	7	5	0	3	2.67	61.9
P-04	174	173	49	46	89.33	45	52	51	49.33	31	30	21	27.33	84.29
P-05	5	2	3	1	2	1	0	2	1	3	2	0	1.67	66.67
P-06	4	1	1	1	1	2	0	1	1	0	0	0	0	100
P-07	5	0	0	0	0	0	0	0	0	0	0	0	0	100
P-08	58	34	34	40	36	37	21	28	28.67	-	-	-	-	50.57
P-09	4	0	0	0	0	0	2	0	0.67	-	-	-	-	83.33
P-10	4	0	1	0	0.33	0	0	0	0	-	-	-	-	100
P-11	39	38	18	18	24.67	22	28	17	22.33	-	-	-	-	42.74
P-12	12	8	2	3	4.33	2	0	1	1	-	-	-	-	91.67
P-13	9	1	5	4	3.33	4	3	4	3.67	-	-	-	-	59.26
P-14	12	8	6	3	5.67	2	4	4	3.33	-	-	-	-	72.22
P-15	163	98	67	150	105	75	95	72	80.67	-	-	-	-	50.51
P-16	6	5	12	5	7.33	0	7	4	3.67	-	-	-	-	38.89
P-17	65	30	19	6	18.33	6	17	3	8.67	-	-	-	-	86.67
P-18	170	126	146	39	103.67	32	61	78	57	-	-	-	-	66.47

Return to article view

The MSR behavior throughout the pilot trial. ID: subject identification; SMSR: starting seizure monthly rate; M1, …, M9: month 1 until 9; TAR: trimestral average rate; SR: seizure rate reduction in percent; -: not computed